Companies/Ensysce Biosciences, Inc.

Company profile

Ensysce Biosciences, Inc.

NASDAQ: ENSC · Healthcare · Biotechnology

PublicHQ La Jolla, CACIK 0001716947Reports USD

#701 of 1,394 Healthcare companies by revenue37th-percentile growth

EA Score

31D

FH 25DQ 27GM 53SS 34

v0.1 · 65/100 weight · provisional

↑ 3-yr revenue growth, balance-sheet leverage · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

$1.5M

Rev growth YoY (TTM)

-76.6%

Net income (FY)

-$10.2M

Employees

Market cap

$2.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$5.1M$5.1M2025

Net income-$10.2M-$10.2M2025

Operating income-$10.2M-$10.2M2025

Total assets$7.5M$7.5M2025

Liabilities$4.6M$4.6M2025

Equity$3.2M$3.2M2025

Revenue trend

FY2021 – FY2025 · USD

$3.9M

FY21

$3.5M

FY22

$2.5M

FY22

$2.2M

FY23

$5.2M

FY24

$5.1M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

MPAR100%

By geography

Not disclosed.

The read

Ensysce Biosciences, Inc. booked $5.1M in FY2025 revenue, contracting 2.8% year over year — slower than 63% of Healthcare companies we track, at a -200.8% net margin.

Peers · Healthcare

Oragenics, Inc.46D Reliq Health Technologies Inc.——Vivos Therapeutics, Inc.38D Artelo Biosciences, Inc.——

Key facts

CEOD. Lynn Kirkpatrick

SectorHealthcare

IndustryBiotechnology

HeadquartersLa Jolla, CA

ExchangeNASDAQ: ENSC

Employees7

IPO date2018-03-14

Latest filings

8-K2026-05-22 8-K2026-05-15 10-Q2026-05-15 8-K2026-04-08 8-K2026-04-03 8-K2026-03-30 8-K2026-03-30 10-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.